This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mascia, L. Articles by Pluta, R. M. Search for Related Content PubMed PubMed Citation Articles by Mascia, L. Articles by Pluta, R. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Stroke. 2001;32:1185.)
© 2001 American Heart Association, Inc.

Original Contributions

Temporal Relationship Between Endothelin-1 Concentrations and Cerebral Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage

L. Mascia, MD; L. Fedorko, MD, PhD; D. J. Stewart, MD; F. Mohamed, BSc; K. terBrugge, MD; V. M. Ranieri, MD M. C. Wallace, MD

From the Department of Anaesthesia, Toronto General Hospital (L.M., L.F.); Division of Cardiology, St Michael Hospital, (D.J.S., F.M.); Division of Neuroradiology, Toronto Western Hospital; and Division of Neurosurgery, Toronto Western Hospital (M.C.W.), University of Toronto, Toronto, Canada); and the Department of Surgery, Anesthesia Section, University of Pisa, Pisa, Italy (V.M.R.).

Correspondence to Luciana Mascia, MD, Dipartimento di Emergenza e Trapianti D’Organo, Sezione di Anestesiologia e Rianimazione, Universitá di Bari, Ospedale Policlinico; Piazza G Cesare 11, 70122, Bari, Italy. E-mail lmascia{at}teseo.it

Background and Purpose—Endothelin 1 (ET-1) is a potent vasoconstrictor that may play a role in cerebral vasospasm following subarachnoid hemorrhage (SAH). However, data regarding its pathogenic role in the development of vasospasm are controversial. We planned a prospective, observational clinical study to investigate the temporal relationship between increased ET-1 production and cerebral vasospasm or other neurological sequelae after SAH.

Methods—ET-1 levels in cerebrospinal fluid (CSF) were measured in 20 SAH patients from admission (within 24 hours from the bleeding) until day 7. Patients received a daily transcranial Doppler study and a neurological evaluation. On day 7, angiography was performed to verify the degree and extent of vasospasm. Patients were then classified as having (1) clinical vasospasm, (2) angiographic vasospasm, (3) no vasospasm, or (4) poor neurological condition without significant vasospasm (low Glasgow Coma Scale score [GCS]).

Results—On admission, ET-1 levels were increased in the low-GCS group compared with the other groups (P=0.04). On day 4 ET-1 levels were not significantly different among groups, whereas on day 7 ET-1 levels were significantly increased in both the clinical vasospasm and low-GCS groups compared with the angiographic vasospasm and no vasospasm groups (P<0.005). Moreover, when the low-GCS group was excluded, there was a significant relationship between vasospasm grade and CSF ET-1 levels (R²=0.73).

Conclusions—CSF ET-1 levels were markedly elevated in patients with clinical manifestations of vasospasm (day 7) and with a poor neurological condition not related to vasospasm. However, ET-1 levels were low in clinical vasospasm patients before clinical symptoms were evident (day 4) and remained low in angiographic vasospasm patients throughout the study period. Thus, our data suggest that CSF ET-1 levels are increased in conditions of severe neuronal damage regardless whether this was due to vasospasm or to the primary hemorrhagic event. In addition, CSF ET-1 levels paralleled the neurological deterioration but were not predictive of vasospasm.

Editorial Comment

Endothelin-1 in Vasospasm After SAH

Ryszard M. Pluta, MD, PhD, Guest Editor

Surgical Neurology Branch National Institute of Neurological Disorders and Stroke, Bethesda, Maryland

This article has been cited by other articles:

				A. Kramer and J. Fletcher Do Endothelin-Receptor Antagonists Prevent Delayed Neurological Deficits and Poor Outcomes After Aneurysmal Subarachnoid Hemorrhage?: A Meta-Analysis Stroke, October 1, 2009; 40(10): 3403 - 3406. [Abstract] [Full Text] [PDF]

				C.-L. Lin, A. S. Dumont, S.-C. Wu, C.-J. Wang, S.-L. Howng, Y.-F. Huang, W.-Y. Wong, N. F. Kassell, A. Y. Jeng, and A.-L. Kwan 17{beta}-Estradiol Inhibits Endothelin-1 Production and Attenuates Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage. Experimental Biology and Medicine, June 1, 2006; 231(6): 1054 - 1057. [Abstract] [Full Text] [PDF]

				C. O. Borel, A. McKee, A. Parra, M. M. Haglund, A. Solan, V. Prabhakar, H. Sheng, D. S. Warner, L. Niklason, and A. Bhardwaj Possible Role for Vascular Cell Proliferation in Cerebral Vasospasm After Subarachnoid Hemorrhage * Editorial Comment Stroke, February 1, 2003; 34(2): 427 - 433. [Abstract] [Full Text] [PDF]